Indian Pharma On A Profit Trip(s)
Business Today|July 25, 2021
Whether WTO approves India-South Africa proposal for TRIPS waiver or not, Indian industry will remain pivotal to global plans to tackle pandemics
Joe C. Mathew
Indian Pharma On A Profit Trip(s)

In the first week of May, Hyderabad-based Natco Pharma approached the Supreme Court with an unusual request. It said it wanted to produce the low-cost generic version of Baricitinib, a patent protected medicine for Covid-19 treatment, and sought a directive to the Drug Controller General of India (DCGI) to quickly dispose of its applications for Emergency Use Authorisation (EUA) and clinical trial waiver. It sought similar directions for another experimental Covid-19 drug Molnupiravir. It also asked the court to ask the Indian Patent Office to expedite its request for Compulsory Licence to bypass market exclusivity of the patent holder, Eli Lilly. Natco said without the regulatory hurdles, it can bring down the per person cost (for a two-week regimen) of Baricitinib from ₹42,287 (innovator's price) to ₹420. But even before the court looked into the case, Natco received EUA. It launched the product at the pre-decided price without waiting for Compulsory Licence.

Natco’s action was fit case for a legal challenge from the patent owner over infringement of intellectual property rights (IPR). However, instead of a legal notice, on May 17, Lilly gave Natco a voluntary licence — a royalty-free, non-exclusive licence allowing it to continue selling the product. Lilly also granted similar licences for making and selling Baricitinib to over half-a-dozen local competitors of Natco. Luca Visini, Managing Director, Lilly India, considers this as proof of Lilly’s commitment to support India in its fight against Covid-19 by making available its breakthrough medicines. “We will continue to explore other initiatives to support patients and the healthcare system in India,” says Visini. Around the same time, US-based Merck (MSD) signed non-exclusive voluntary licensing agreements with five Indian generic companies for Molnupiravir.

This story is from the July 25, 2021 edition of Business Today.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

This story is from the July 25, 2021 edition of Business Today.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

MORE STORIES FROM BUSINESS TODAYView All
Leapfrogging Into The Future
Business Today India

Leapfrogging Into The Future

Gen AI is the future. In India, this revolutionary technology has already penetrated deep into the country's banking sector

time-read
6 mins  |
March 31, 2024
The Visionary
Business Today India

The Visionary

In a career spanning nearly four decades, Uday Kotak, a firstgeneration entrepreneur, has not only created a bank of size but also built an institution, which offers a wide range of financial services, from asset management and insurance to securities

time-read
10+ mins  |
March 31, 2024
Is The Tie Dead?
Business Today India

Is The Tie Dead?

Maybe not. But it is no longer de facto office wear and is slowly being reduced to something to be worn only on special occasions

time-read
4 mins  |
March 31, 2024
"Bring in experts to understand customers"
Business Today India

"Bring in experts to understand customers"

Qualcomm-backed ideaForge Technology is a Mumbai-based drone manufacturer

time-read
1 min  |
March 31, 2024
SHAKING IT UP
Business Today India

SHAKING IT UP

AMERICAN PHARMA MAJOR ELI LILLY SEES INDIA AS ITS LAUNCHPAD FOR A NEW GROWTH TRAJECTORY, USING ITS NEW DRUGS FOR DIABETES AND OBESITY AS THE FUEL. WILL THIS STRATEGIC PIVOT WORK?

time-read
9 mins  |
March 31, 2024
"Besides China, no one can match the scale that India offers"
Business Today India

"Besides China, no one can match the scale that India offers"

Romal Shetty, CEO of Deloitte South Asia, says innovations coming out of India are being replicated globally, and the country holds great strategic value for the Big 4 firm

time-read
7 mins  |
March 31, 2024
PICKING THE WINNERS
Business Today India

PICKING THE WINNERS

The methodology used for the Business Today-KPMG Best Banks and NBFCs Survey 2022-23

time-read
8 mins  |
March 31, 2024
THE SMALL FIRM'S BEST FRIEND
Business Today India

THE SMALL FIRM'S BEST FRIEND

Lendingkart, a fintech that posted its highest-ever PAT in FY23, is making credit available to MSMEs in India's far-flung areas

time-read
3 mins  |
March 31, 2024
HELPING HAND
Business Today India

HELPING HAND

From helping financial institutions with e-verifications to aiding them in fraud detection and prevention, Perfios is bridging the gap between data and insights

time-read
3 mins  |
March 31, 2024
THE OMNIPRESENT PLATFORM
Business Today India

THE OMNIPRESENT PLATFORM

Fintech major Razorpay has undergone many diversifications. Yet, its core premise remains the same: make the movement of money simpler

time-read
4 mins  |
March 31, 2024